1. Home
  2. Mandates
  3. Vinge advises Vicore Pharma in connection with its listing on Nasdaq Stockholm (1)

Mandate Vinge advises Vicore Pharma in connection with its listing on Nasdaq Stockholm

September 23, 2019

Vinge advises Vicore Pharma Holding AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market.

The prospectus was published on 16 September 2019 and the trading on Nasdaq Stockholm will commence on 27 September 2019.

Vicore Pharma is a Swedish rare disease pharmaceutical company focused on interstitial lung diseases and related indications. The company currently has two drug development programs in preclinical or clinical phase.

Vinge’s team has primarily consisted of Jesper Schönbeck, Nils Fredrik Dehlin, Astrid Isberg, Emelie Svanberg, Viktor Bergsten and Sofia Bergenstråhle.

Jerker Kjellander is a new partner in Skåne

 Dispute resolution expert Jerker Kjellander has been elected as a partner in Vinge’s Skåne office.
November 20, 2020

Amendments to the Swedish Competition Act provide extended powers for the Swedish Competition Authority

Update 13 November 2020. Early in 2021, the Swedish Competition Act (2008: 579) will be amended in several important respects. The background to the amendments is Directive (EU) 2019/1 of the European Parliament and of the Council, which aims to harmonize the investigative and sanctioning powers of the European competition authorities in their enforcement of the EU competition rules. Undertakings active in Sweden will be affected by the amendments in several ways.
October 12, 2020

Vinge contributes to IUMI Eye

 International Union of Marine Insurers (IUMI) is preparing for its first web based conference – Stockholm 2020 – of which Vinge is a proud sponsor. In the latest edition of IUMI Eye, published just in time for the conference, Vinge’s Paula Bäckdén and Sweden Insurance’s senior advisor Mikaela Tamm discuss the implications of waiving liability limitations.
September 15, 2020